Acute Severe COPD Exacerbation: NIV and Invasive Ventilation — Comprehensive ICU Management

[1]

Definition and GOLD context

An acute exacerbation of COPD (AECOPD) is an acute, sustained worsening of dyspnoea, cough, and/or sputum beyond day-to-day variation that prompts a change in regular medication. The GOLD 2024 report defines it as an event characterised by increased respiratory symptoms, and emphasises that exacerbations drive disease progression, hospitalisation, mortality, and healthcare cost.[1]

GOLD stratifies exacerbation severity by the clinical impact:

• Mild — treated with short-acting bronchodilators only (SABA/SAMA).
• Moderate — requires antibiotics and/or systemic corticosteroids in addition to bronchodilators.
• Severe — the patient has acute respiratory failure needing ventilatory support (NIV or invasive mechanical ventilation) or develops haemodynamic instability; this is the domain of the ICU.[1]

The NICE NG115 guideline aligns with GOLD: it recommends controlled oxygen, systemic corticosteroids, antibiotics guided by sputum purulence, and NIV for hypercapnic respiratory failure, and stresses early pulmonary rehabilitation after discharge.[1]

In the ICU the entity of interest is the severe AECOPD with hypercapnic (type 2) respiratory failure and respiratory acidosis — the low-pH, high-CO2 patient for whom bilevel NIV was designed and proven.[1][2]

Causes and triggers — infection is number one

Around 70 per cent of exacerbations are infective, with the remainder due to environmental exposure or a non-infective complication. Identifying and treating the trigger is as important as supporting ventilation.[1]

Pathophysiology — why the COPD patient retains CO2

The respiratory failure of an AECOPD is type 2 (hypercapnic) with a respiratory acidosis. Four mechanisms converge, and oxygen therapy can worsen all of them:[1]

1. Increased load, reduced capacity. Bronchospasm, mucosal oedema, and secretions raise airway resistance; dynamic hyperinflation (gas trapping) adds an elastic threshold load — the patient must generate a pressure equal to the intrinsic PEEP (auto-PEEP) before any airflow begins. The respiratory muscles fatigue, alveolar ventilation falls, and PaCO2 climbs. [1]

2. V/Q mismatch. Areas of low ventilation relative to perfusion increase physiological dead space and venous admixture, raising PaCO2 and lowering PaO2. [1]

3. The Haldane effect. Deoxygenated haemoglobin carries CO2 readily (as carbamino compounds and bicarbonate). Oxygenating haemoglobin releases this CO2. In the ventilation-limited patient the released CO2 cannot be cleared, so PaCO2 rises acutely — the molecular basis of oxygen-induced hypercapnia. [1]

4. Loss of hypoxic pulmonary vasoconstriction. A high FiO2 abolishes hypoxic vasoconstriction, redistributing blood to poorly ventilated units and increasing dead space. [1]

Clinical presentation

The patient is usually a known COPD sufferer (though AECOPD may be the first presentation). Typical features: [1]

• Breathlessness worsening over hours to days, with accessory muscle use, pursed-lip breathing, and inability to speak in full sentences
• Tachypnoea initially, then bradypnoea as the patient tires — a pre-arrest sign; a silent chest signals exhaustion and impending arrest
• Wheeze and a prolonged expiratory phase
• Productive cough with increased sputum volume or purulence if infective
• Confusion or drowsiness from CO2 narcosis (a falling GCS is a relative contraindication to NIV and a trigger to intubate)
• Signs of haemodynamic compromise (tachycardia, hypotension, atrial fibrillation) in the advanced case
• Warm peripheries, a bounding pulse, and asterixis (CO2 flap) in severe hypercapnia [1]

A sudden unilateral deterioration with tracheal deviation suggests tension pneumothorax — treat it before treating the exacerbation. [1]

Severity — the arterial blood gas drives everything

The arterial blood gas is the single most important investigation. The pH defines severity and dictates the level of respiratory support.[1][2]

Investigations

1. Arterial blood gas — the pivotal test. Record pH, PaCO2, PaO2, bicarbonate, base excess. A raised bicarbonate confirms chronic CO2 retention now acutely decompensated. Recheck after one hour of NIV.
2. Chest X-ray — find the trigger and the mimics: pneumothorax, consolidation, pulmonary oedema, pleural effusion.
3. ECG — atrial fibrillation and right heart strain (cor pulmonale) are common; exclude myocardial ischaemia.
4. Full blood count, electrolytes, CRP — polycythaemia from chronic hypoxia, hypokalaemia from beta-agonist therapy, an infective marker.
5. Sputum and blood cultures — if infective, taken before antibiotics.
6. Troponin and BNP — if a cardiac contribution is suspected.
7. Venous blood gas — a useful screen; a normal venous pH makes a significant acidosis unlikely, but an arterial gas is definitive.
8. Theophylline level — only if the patient takes a methylxanthine. [1]

Management — the bundle and the escalation

Management runs in parallel: the medical bundle (oxygen, bronchodilators, steroids, antibiotics) is applied to every patient, while respiratory support is escalated according to the ABG pH.[1][1]

The medical bundle

[1]

The escalation pathway — controlled oxygen to NIV to intubation

Respiratory support is ABG-driven. The FlowSteps below trace the complete pathway from the acidotic ward patient to the intubated ICU patient.[1][2]

[1]

Bilevel NIV — settings and technique

NIV in AECOPD is bilevel (BiPAP), not CPAP. CPAP alone does not unload the work of breathing against auto-PEEP and is not first-line for COPD. The IPAP (inspiratory positive airway pressure) unloads the fatigued muscles and boosts tidal volume; the EPAP (expiratory positive airway pressure) splints the airways open and counteracts intrinsic PEEP, lowering the pressure the patient must generate to trigger a breath.[2][4]

Technique points:

• Use a well-fitting oronasal (full-face) mask first; switch to a nasal or total-face mask if leak or claustrophobia is a problem.
• Let the patient hold the mask to the face to build tolerance before strapping it on.
• Set a backup respiratory rate (~12-14) so the ventilator supports an apnoeic or bradypnoeic patient, but allow spontaneous triggering.
• Humidify, suction regularly, and allow brief "sip and peel-off" breaks for the cooperative patient.
• Recheck the ABG at one hour — the pH trend at one hour is the best predictor of NIV success.[1]

Contraindications to NIV

Absolute (or near-absolute) — favour intubation: respiratory arrest, inability to protect the airway (low GCS, copious secretions), severe agitation or confusion precluding cooperation, haemodynamic instability, facial trauma/surgery, upper airway obstruction. [1]

Relative — proceed with caution in a monitored area: pH <7.25, pneumonia on CXR, and the patient who fails to improve at one hour.[2]

NIV versus invasive ventilation — when to choose which

When to intubate — recognising NIV failure

NIV fails in roughly 15-25 per cent of AECOPD patients. The art is recognising failure early, because a delayed intubation after a failed NIV trial carries a higher risk than a timely one.[1][2]

Intubate when any of the following are present: [1]

1. pH <7.25 that is not improving after one hour of optimised NIV — the single most important objective criterion.
2. Worsening GCS / decreasing consciousness — CO2 narcosis; the patient cannot protect the airway.
3. Respiratory arrest or peri-arrest — bradypnoea, silent chest, loss of respiratory effort.
4. Haemodynamic instability — hypotension, sustained tachycardia, or new arrhythmia.
5. Copious secretions that NIV cannot clear, or agitation/confusion precluding mask tolerance.
6. Failure to improve at the one-hour reassessment (worsening pH, rising PaCO2, rising respiratory rate).[1]

Invasive ventilation — the COPD rules

The goal in the intubated COPD patient is to deliver an adequate tidal volume while leaving enough time for full exhalation, so gas is not trapped and auto-PEEP does not accumulate. Failure to do this produces dynamic hyperinflation, hypotension, barotrauma, and the auto-PEEP arrest.[1]

[1] [1]

Weaning and early mobilisation

Once the patient is improving — pH normalising, PaCO2 falling, secretions controlled, trigger treated — begin weaning NIV: reduce IPAP in 2 cmH2O steps, increase off-periods, and use a Hudson mask for meals. Do not stop NIV abruptly. [1]

For the intubated patient, use daily sedation breaks and a spontaneous breathing trial (SBT) once FiO2 is <40 per cent, PEEP <8, and the patient is triggering. COPD patients are at high risk of prolonged ventilation; a protocolised weaning approach and early mobilisation reduce ventilator-days. Early mobilisation — sitting out of bed, marching on the spot, active limb exercises within 24-48 hours of stability — prevents deconditioning and steroid myopathy and is part of standard ICU rehabilitation.[1][1]

Evidence and landmark trials

[1]

Prognosis

Hospital mortality for an acidotic AECOPD treated with NIV is around 8-10 per cent, rising to 20-25 per cent when invasive ventilation is required.[1][2] Readmission within 90 days is common (~20 per cent) and predicts poorer long-term survival. Poor prognostic features include advanced age, low BMI, comorbid cardiac disease, ongoing smoking, and severe baseline airflow obstruction. Long-term non-invasive domiciliary ventilation, smoking cessation, optimised inhaler therapy, and pulmonary rehabilitation reduce future exacerbations and are part of the discharge bundle.[1][1]

Clinical pearls

Red flags

Exam SAQ

[1]

References

1. [1]Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial Lancet, 2000.PMID 10859037
2. [2]Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis BMJ, 2003.PMID 12543832
3. [3]Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease Ann Intern Med, 1987.PMID 3492164
4. [4]Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, Simonneau G, Benito S, Gasparetto A, Lemaire F. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease N Engl J Med, 1995.PMID 7651472